Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancer.
暂无分享,去创建一个
E. Ricevuto | C. Ficorella | F. Martella | V. Flati | V. Tombolini | G. Gravina | L. Biordi | C. Festuccia
[1] P. Abel,et al. Predictive value of PTEN and AR coexpression of sustained responsiveness to hormonal therapy in prostate cancer--a pilot study. , 2008, Neoplasia.
[2] A. Angelucci,et al. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386. , 2008, The Journal of urology.
[3] C. Vicentini,et al. Akt down‐modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors , 2008, The Prostate.
[4] C. Vicentini,et al. Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients. , 2007, Oncology reports.
[5] R. Vessella,et al. Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer. , 2007, Endocrine-related cancer.
[6] J. Kreisberg,et al. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. , 2007, Current cancer drug targets.
[7] Shunyou Wang,et al. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. , 2007, Cancer research.
[8] D. Troyer,et al. Determining Risk of Biochemical Recurrence in Prostate Cancer by Immunohistochemical Detection of PTEN Expression and Akt Activation , 2007, Clinical Cancer Research.
[9] Xiuli Wang,et al. Histone deacetylase inhibitor trichostatin a potentiates doxorubicin‐induced apoptosis by up‐regulating PTEN expression , 2007, Cancer.
[10] Daniel J. Freeman,et al. Genetic background controls tumor development in PTEN-deficient mice. , 2006, Cancer research.
[11] M. Gleave,et al. Loss of PTEN is associated with progression to androgen independence , 2006, The Prostate.
[12] S. Morrison,et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells , 2006, Nature.
[13] H. Stoop,et al. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi‐allelic gene deletion , 2006, The Journal of pathology.
[14] L. Martínez-Piñeiro,et al. Molecular biology in prostate cancer , 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
[15] A. Angelucci,et al. Retracted: Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro , 2005, International journal of cancer.
[16] T. H. van der Kwast,et al. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. , 2005, Cancer research.
[17] A. Angelucci,et al. Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples. , 2005, International journal of oncology.
[18] P. Scardino,et al. High Levels of Phosphorylated Form of Akt-1 in Prostate Cancer and Non-Neoplastic Prostate Tissues Are Strong Predictors of Biochemical Recurrence , 2004, Clinical Cancer Research.
[19] J. Isaacs,et al. Enhanced Redundancy in Akt and Mitogen-activated Protein Kinase-induced Survival of Malignant versus Normal Prostate Epithelial Cells , 2004, Cancer Research.
[20] P Roy-Burman,et al. Genetically defined mouse models that mimic natural aspects of human prostate cancer development. , 2004, Endocrine-related cancer.
[21] J. Veltman,et al. Loss of a small region around the PTEN locus is a major chromosome 10 alteration in prostate cancer xenografts and cell lines , 2004, Genes, chromosomes & cancer.
[22] D. Leroith,et al. PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells , 2004, Oncogene.
[23] P. Pandolfi,et al. Pten Dose Dictates Cancer Progression in the Prostate , 2003, PLoS biology.
[24] P. Nelson,et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. , 2003, Cancer cell.
[25] D. Tindall,et al. The role of PTEN in the progression and survival of prostate cancer. , 2003, Minerva endocrinologica.
[26] C. Bucana,et al. Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] F. Sarkar,et al. Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] D. Tindall,et al. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. , 2001, Endocrinology.
[29] R. Vessella,et al. Increased AKT Activity Contributes to Prostate Cancer Progression by Dramatically Accelerating Prostate Tumor Growth and Diminishing p27Kip1 Expression* , 2000, The Journal of Biological Chemistry.
[30] T. Mak,et al. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. , 2000, Cancer research.
[31] C. Cordon-Cardo,et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[32] C. Sawyers,et al. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[33] Carlos Cordon-Cardo,et al. Pten is essential for embryonic development and tumour suppression , 1998, Nature Genetics.
[34] R. Vessella,et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[35] S. Keam,et al. Spotlight on Bicalutamide 150mg in the Treatment of Locally Advanced Prostate Cancer , 2007, Drugs & aging.
[36] M. Resnick,et al. Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model. , 2005, The Prostate.